Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News | May 21, 2012

May 15, 2012 –– As EuroPCR 2012 gets underway, Medtronic Inc.announced that the Resolute Integrity Coronary Stent...

News | April 17, 2012

April 12, 2012 – Abbott announced approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the...

News | April 06, 2012

April 6, 2012 — Boston Scientific Corp. announced results from a quantitative coronary angiographic (QCA) analysis...

News | April 02, 2012

April 2, 2012 — Boston Scientific announced its support of the HORIZONS II AMI clinical trial, which is designed to...

The Boston Scientific Promus Element stent.

Feature | March 29, 2012

March 29, 2012 – Two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and...

News | March 29, 2012

March 29, 2012 — In the second year of an ongoing trial, the Resolute zotarolimus-eluting stent (Medtronic) achieved...

Feature | March 27, 2012

March 27, 2012 — Biodegradable polymer drug-eluting stents...

Feature | March 16, 2012 | Mark Paquin

April 15, 2012, will mark the 10th anniversary of the approval of the first drug-eluting...

News | March 09, 2012

March 9, 2012 — Boston Scientific Corp. announced the launch of the Promus Element everolimus-eluting coronary...

News | March 06, 2012

March 6, 2012 — In a development that brings advanced combination therapy treatment of...

The Boston Scientific Ion stent.

News | February 24, 2012

February 24, 2012 ­– The U.S. Food and Drug Administration (FDA) this week granted the first coronary stent...

Technology | February 20, 2012

February 20, 2012 — Medtronic announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity...

News | February 01, 2012

February 1, 2012 — Boston Scientific announced the first patient use and European market launch of the Promus...

News | January 24, 2012

January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all...

News | January 09, 2012

January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI)...

Overlay Init